Search results
Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells. Discover our mission.
- About us
Orano Med seeks to develop a new generation of targeted...
- Targeted Alpha Therapy
Orano Med has equipped itself with all the tools necessary...
- Pipeline
Based on the unique properties of 212Pb, Orano Med is...
- Industrial platform
The patented, entirely chemical process, developed by Orano...
- About us
People also ask
What is Orano Med?
Where is Orano Med manufactured?
Why did Orano Med receive FDA approval?
What is Orano Med doing with 212 PB?
Feb 12, 2024 · Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 ( 212 Pb), a rare alpha-emitting...
Feb 12, 2024 · RadioMedix, Inc. and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to AlphaMedix TM (212 Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor ...
Mar 16, 2022 · Orano Med, a subsidiary of the Orano group, has taken important steps forward in the development of treatments known as "targeted alpha therapy" with lead-212, an innovative approach to fighting cancers with limited therapeutic options.
Jan 3, 2022 · Orano Med is a clinical-stage biotechnology company with the ambition to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 ( 212 Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emmiter Therapy (TAT).
Orano Med (previously AREVA Med) is Macrocyclics’ parent company since 2011. Orano Med is a nuclear biotech company developing innovative therapies in oncology.